Research chair named after Dr. Salem
St. Luke’s Episcopal Hospital has established the Philip A. Salem, MD, Chair in Cancer Research.
PHILIP A. SALEM, MD
St. Luke's Episcopal Hospital has established the Philip A. Salem, MD, Chair in Cancer Research. This is the first chair in cancer research established at the Houston-based hospital which is part of the Texas Medical Center.
Dr. Salem is the director of the cancer research program at St. Luke's. His groundbreaking work in chemoprevention, including the link between chronic gastrointestinal infections and the risk of cancer, has led to research focusing on isolating and treating precancerous infections.
FDA Approves Encorafenib/Cetuximab Plus mFOLFOX6 for Advanced BRAF V600E+ CRC
December 20th 2024The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.
